Evidence map›Paper›PMID 42762383›Full record

ArticleHepatology international2026

Dynamic changes in controlled attenuation parameter (CAP) improve prognostic prediction for CHB patients with significant fibrosis and cirrhosis.

Xiaowei Ai, Mengyang Zhang, Shuyan Chen, Xinyu Zhao, Jialing Zhou, Tongtong Meng, Bingqiong Wang, Chenglin Sun, Xiao Han, Yankun Gao and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Hepatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xiaowei Ai *Liver Research Center, Beijing Friendship Hospital, Capital Medical University, State Key Lab of Digestive Health, National Clinical Research Center of Digestive Diseases, Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis, Beijing, China.
Mengyang Zhang *Liver Research Center, Beijing Friendship Hospital, Capital Medical University, State Key Lab of Digestive Health, National Clinical Research Center of Digestive Diseases, Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis, Beijing, China.
Shuyan ChenLiver Research Center, Beijing Friendship Hospital, Capital Medical University, State Key Lab of Digestive Health, National Clinical Research Center of Digestive Diseases, Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis, Beijing, China.
Xinyu ZhaoClinical Epidemiology and EBM Unit, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Jialing ZhouLiver Research Center, Beijing Friendship Hospital, Capital Medical University, State Key Lab of Digestive Health, National Clinical Research Center of Digestive Diseases, Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis, Beijing, China.
Tongtong MengLiver Research Center, Beijing Friendship Hospital, Capital Medical University, State Key Lab of Digestive Health, National Clinical Research Center of Digestive Diseases, Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis, Beijing, China.
Bingqiong WangLiver Research Center, Beijing Friendship Hospital, Capital Medical University, State Key Lab of Digestive Health, National Clinical Research Center of Digestive Diseases, Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis, Beijing, China.
Chenglin SunLiver Research Center, Beijing Friendship Hospital, Capital Medical University, State Key Lab of Digestive Health, National Clinical Research Center of Digestive Diseases, Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis, Beijing, China.
Xiao HanLiver Research Center, Beijing Friendship Hospital, Capital Medical University, State Key Lab of Digestive Health, National Clinical Research Center of Digestive Diseases, Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis, Beijing, China.
Yankun GaoLiver Research Center, Beijing Friendship Hospital, Capital Medical University, State Key Lab of Digestive Health, National Clinical Research Center of Digestive Diseases, Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis, Beijing, China.
Xiaoning WuLiver Research Center, Beijing Friendship Hospital, Capital Medical University, State Key Lab of Digestive Health, National Clinical Research Center of Digestive Diseases, Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis, Beijing, China.
Hong You *Liver Research Center, Beijing Friendship Hospital, Capital Medical University, State Key Lab of Digestive Health, National Clinical Research Center of Digestive Diseases, Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis, Beijing, China. youhong30@sina.com.
Yameng Sun *Liver Research Center, Beijing Friendship Hospital, Capital Medical University, State Key Lab of Digestive Health, National Clinical Research Center of Digestive Diseases, Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis, Beijing, China. sunyamenggo@163.com.ORCID http://orcid.org/0000-0003-2981-9936

Funding

Beijing High-Level Innovation and Entrepreneurship Talent Support Program young backbone talent projects NO.20250369Beijing Municipal Administration of Hospitals Incubating Program PX2024005National Key Research and Development Program of China 2023YFC2306900National Natural Science Foundation of China 82470644
6 · The paper itself

Abstract

BACKGROUND &

aimsThe coexistence of hepatic steatosis and chronic hepatitis B (CHB) is becoming increasingly common. Although the controlled attenuation parameter (CAP) has been widely used to quantify hepatic steatosis in CHB patients, the prognostic value of longitudinal changes in CAP remains unknown. This study aimed to evaluate whether dynamic changes in CAP are associated with liver-related events (LREs) in CHB patients undergoing antiviral therapy.

methodsCHB patients with significant fibrosis or cirrhosis before antiviral therapy were included. CAP was used to assess hepatic steatosis. LREs were defined as hepatic decompensations, hepatocellular carcinoma (HCC), liver transplantation, or liver-related death. Joint models were employed to analyze associations between longitudinal measurements and risk of LREs.

resultsA total of 573 CHB patients were followed for a median of 6.9 years, during which 51 LREs occurred. CAP-dynamics independently predicted LREs (per 10 dB/m increase aHR 0.86, 95% CI 0.78-0.96, p = 0.006). After adjusting for LSM-dynamics, CAP-dynamics remained an independent factor for LREs (per 10 dB/m increase aHR 0.85, 95% CI 0.77-0.95, p = 0.005). The multivariate joint model integrating CAP and LSM dynamics improved predictive performance compared with LSM alone, with the 7-year AUROC increasing from 0.70 to 0.75. CAP exceeding 236 dB/m over time was associated with a reduced risk of LREs (aHR 0.67, 95% CI 0.53-0.84, p < 0.001).

conclusionIn on-treatment CHB patients with significant fibrosis, the dynamics of CAP were associated with the risk of LREs. Longitudinal monitoring of CAP can offer extra prognostic value.

Indexed as

Chronic hepatitis BHepatic steatosisJoint modelsLiver-related events

Identifiers

PMID42762383

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.